Merck is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant’s rare-disease business.
The deal for Acceleron, which has a market value of around $ 11 billion, could be announced this week, assuming talks don’t fall apart, the people said.